Literature DB >> 8961473

Staphylococcal bacteremia in cancer patients: risk factors and outcome in 134 episodes prior to and after introduction of quinolones into infection prevention in neutropenia.

E Kukuckova1, S Spanik, I Ilavska, L Helpianska, E Oravcova, J Lacka, I Krupova, S Grausova, P Koren, I Bezakova, E Grey, M Balaz, M Studena, A Kunova, K Torfs, J Trupl, S Korec, K Stopkova, V Krcmery.   

Abstract

A total of 134 episodes of staphylococcal bacteremia (SBE) appearing among 9987 admissions, and 979 episodes of bacteremia in cancer patients within 5 years, were analyzed for risk factors, clinical course and outcome; 64 were monomicrobial and 70 polymicrobial. The most frequent risk factors were acute leukemia, catheter insertion, long-lasting neutropenia, and prior prophylaxis with quinolones. There was no significant difference between polymicrobial and monomicrobial SBE in risk factors. The two groups differed only in the source of bacteremia (gastrointestinal and respiratory-tract infections were more common in monomicrobial SBE) and etiology-Staphylococcus aureus appeared more frequently in monomicrobial than in polymicrobial bacteremia (20.3% compared to 4.3%, P < 0.05). More complications (14.3%) such as abscesses, endocarditis, etc. appeared in the group of polymicrobial SBE (P < 0.05). No difference was observed in clinical course and outcome between monomicrobial and polymicrobial SBE. The incidence of SBE has increased since 1991, when quinolones were first used in prophylaxis in afebrile neutropenia at our center; however, the infection-associated mortality in monomicrobial SBE was low (4.3%).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8961473     DOI: 10.1007/bf01880640

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  11 in total

1.  Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes.

Authors:  J A Lecciones; J W Lee; E E Navarro; F G Witebsky; D Marshall; S M Steinberg; P A Pizzo; T J Walsh
Journal:  Clin Infect Dis       Date:  1992-04       Impact factor: 9.079

2.  Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.

Authors:  A Cometta; T Calandra; H Gaya; S H Zinner; R de Bock; A Del Favero; G Bucaneve; F Crokaert; W V Kern; J Klastersky; I Langenaeken; A Micozzi; A Padmos; M Paesmans; C Viscoli; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Bacteremia due to viridans streptococci that are highly resistant to penicillin: increase among neutropenic patients with cancer.

Authors:  J Carratalá; F Alcaide; A Fernández-Sevilla; X Corbella; J Lińares; F Gudiol
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

4.  Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.

Authors: 
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

5.  Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit.

Authors:  M A Montecalvo; H Horowitz; C Gedris; C Carbonaro; F C Tenover; A Issah; P Cook; G P Wormser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

6.  Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.

Authors:  M B Edmond; J F Ober; D L Weinbaum; M A Pfaller; T Hwang; M D Sanford; R P Wenzel
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

7.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy.

Authors:  J W Chow; M J Fine; D M Shlaes; J P Quinn; D C Hooper; M P Johnson; R Ramphal; M M Wagener; D K Miyashiro; V L Yu
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

8.  Pseudomonas aeruginosa bacteremia in immunocompromised children: analysis of factors associated with a poor outcome.

Authors:  J E Fergie; S J Shema; L Lott; R Crawford; C C Patrick
Journal:  Clin Infect Dis       Date:  1994-03       Impact factor: 9.079

9.  Evolution of bacterial susceptibility to antibiotics during a six-year period in a haematology unit.

Authors:  B Durand-Gasselin; R Leclercq; F Girard-Pipau; M C Deharvengt; H Rochant; A Astier; J Duval; C Cordonnier
Journal:  J Hosp Infect       Date:  1995-01       Impact factor: 3.926

10.  Sepsis syndrome and associated sequelae in patients at high risk for gram-negative sepsis.

Authors:  K Conboy; L S Welage; C A Walawander; L C Duffy; R C Welliver; M A Zielezny; J T DiPiro; M A Raebel; T H Grasela
Journal:  Pharmacotherapy       Date:  1995 Jan-Feb       Impact factor: 4.705

View more
  1 in total

1.  Bloodstream infection caused by S. aureus in patients with cancer: a 10-year longitudinal single-center study.

Authors:  Omar Yaxmehen Bello-Chavolla; Jessica Paola Bahena-Lopez; Pamela Garciadiego-Fosass; Patricia Volkow; Alejandro Garcia-Horton; Consuelo Velazquez-Acosta; Diana Vilar-Compte
Journal:  Support Care Cancer       Date:  2018-06-08       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.